Sugi Predict

Sugi Predict / Compounds / SCHEMBL9489755

SCHEMBL9489755

SCHEMBL9489755

O=C(O)c1ccc(O)c([N+](=O)[O-])c1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SELL P14151 1/20 0.44
▸ SELP P16109 1/20 0.44
▸ ALDH1A1 P00352 5/20 0.43
▸ TDP1 Q9NUW8 3/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ GPR35 Q9HC97 1/20 0.43
▸ CA1 P00915 3/20 0.42
▸ CA2 P00918 3/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ CDK2 P24941 1/20 0.40
▸ MAPT P10636 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ ESR2 Q92731 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ TSHR P16473 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11669542 0.88 TDP1 (0.47) ALDH1A1TDP1CA1CA2CYP3A4
SCHEMBL2187863 0.86 SELL (0.48) SELLSELPALDH1A1TDP1SMN1; SMN2
SCHEMBL537538 0.81 DTYMK (0.49) ALDH1A1TDP1GPR35CA1CA2
SCHEMBL7693503 0.81 SELL (0.57) SELLSELPALDH1A1TDP1SMN1; SMN2
SCHEMBL8161303 0.80 GPR35 (0.42) ALDH1A1TDP1SMN1; SMN2GPR35CA1
SCHEMBL2057086 0.80 TSHR (0.53) SELLSELPALDH1A1TDP1SMN1; SMN2
SCHEMBL2598195 0.80 TDP1 (0.49) ALDH1A1TDP1CYP3A4ALOX15MAPT
SCHEMBL2057084 0.80 TSHR (0.53) SELLSELPALDH1A1TDP1SMN1; SMN2
SCHEMBL21750002 0.80 ALDH1A1 (0.41) ALDH1A1TDP1SMN1; SMN2CA1CA2
SCHEMBL2956655 0.80 GPR35 (0.42) ALDH1A1TDP1SMN1; SMN2GPR35CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2877462-B1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2019-09-04 — — EP claimed
US-9133161-B2 Processes for preparing isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2015-09-15 — — US claimed
EP-2877462-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS Celgene Corporation (US) 2015-06-03 — — EP claimed
WO-2014018866-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — WO claimed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — US claimed
CN-116457344-B Low molecular weight protein degradation agent and application thereof 凯普托尔治疗学股份有限公司 2026-05-12 — — CN disclosed
US-12331030-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) 2025-06-17 — — US disclosed
WO-2024238872-A2 ISOINDOLINONE-GLUTARIMIDE ANTIBODY CONJUGATES, AND USES THEREOF FIREFLY BIO, INC. (US) 2024-11-21 — — WO disclosed
US-20240294489-A1 LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 — — US disclosed
US-11873287-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating TIANJIN HEMAY PHARMACEUTICAL SCI-TECH CO., LTD (CN) 2024-01-16 — — US disclosed
US-11767295-B2 Isoindole derivative TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2023-09-26 — — US disclosed
CN-116457344-A Low molecular weight protein degradation agent and application thereof 凯普托尔治疗学股份有限公司 2023-07-18 — — CN disclosed
EP-3530652-A1 MODIFIED PHENYLPHTHALIMIDE AND PHARMACEUTICAL COMPOSITION HAVING SAME AS ACTIVE INGREDIENT Keio University (JP) 2019-08-28 — — EP disclosed
CN-108101886-A Piperidine-2,6-diones derivative and its purposes in ulcerative colitis is treated 天津和美生物技术有限公司 2018-06-01 — — CN disclosed
CN-108101887-A Piperidine-2,6-diones derivative and its purposes in Crohn's disease is treated 天津和美生物技术有限公司 2018-06-01 — — CN disclosed
US-9133161-B2 Processes for preparing isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2015-09-15 — — US disclosed
EP-2877462-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS Celgene Corporation (US) 2015-06-03 — — EP disclosed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — US disclosed
WO-2014018866-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — WO disclosed
US-5180419-A Herbicidal 2-(2-imidazolin-2-yl)-benzo-(5-membered)-heterocycles and the use thereof AMERICAN CYANAMID COMPANY (US) 1993-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11767295-B2 Isoindole derivative COX4I1, ALDH1A2, GDI2 SELL 2233/4885SELP 4503/4885ALDH1A1 78/4885
US-20240294489-A1 LOW MOLECULAR WEIGHT PROTEIN DEGRADERS AND THEIR APPLICATIONS MMP2, PSME2, PSME1 SELL 4558/4885SELP 3587/4885ALDH1A1 2024/4885
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS UGT1A1, CYP3A5, CYP3A7 SELL 4105/4885SELP 4301/4885ALDH1A1 347/4885
US-12331030-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating DPYD, PTGDR2, UCK2 SELL 1514/4885SELP 1574/4885ALDH1A1 34/4885
US-11873287-B2 Piperidine-2,6-dione derivatives and ulcerative colitis treating DPYD, PTGDR2, UCK2 SELL 1514/4885SELP 1574/4885ALDH1A1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.